Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 29

1.

Comparison of matched sibling donors versus unrelated donors in allogeneic stem cell transplantation for primary refractory acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT.

Brissot E, Labopin M, Stelljes M, Ehninger G, Schwerdtfeger R, Finke J, Kolb HJ, Ganser A, Schäfer-Eckart K, Zander AR, Bunjes D, Mielke S, Bethge WA, Milpied N, Kalhs P, Blau IW, Kröger N, Vitek A, Gramatzki M, Holler E, Schmid C, Esteve J, Mohty M, Nagler A.

J Hematol Oncol. 2017 Jun 24;10(1):130. doi: 10.1186/s13045-017-0498-8.

2.

T Cell Receptor Excision Circle (TREC) Monitoring after Allogeneic Stem Cell Transplantation; a Predictive Marker for Complications and Clinical Outcome.

Gaballa A, Sundin M, Stikvoort A, Abumaree M, Uzunel M, Sairafi D, Uhlin M.

Int J Mol Sci. 2016 Oct 11;17(10). pii: E1705. Review.

3.

How to select the best available related or unrelated donor of hematopoietic stem cells?

Tiercy JM.

Haematologica. 2016 Jun;101(6):680-7. doi: 10.3324/haematol.2015.141119. Epub 2016 May 31. Review.

4.

Three-dimensional structure discrepancy between HLA alleles for effective prediction of aGVHD severity and optimal selection of recipient-donor pairs: a proof-of-concept study.

Han H, Yuan F, Sun Y, Liu J, Liu S, Luo Y, Liang F, Liu N, Long J, Zhao X, Kong F, Xi Y.

Oncotarget. 2015 Nov 24;6(37):40337-59. doi: 10.18632/oncotarget.5378.

5.

Risk Factors, Pattern and Clinical Outcome of Acute Graft Versus Host Disease in Acute Leukemia Patients Undergoing Allogeneic Stem Cell Transplant.

Gupta A, Punatar S, Gawande J, Mathew L, Bagal B, Kannan S, Khattry N.

Indian J Hematol Blood Transfus. 2015 Dec;31(4):404-12. doi: 10.1007/s12288-014-0499-5. Epub 2015 Jan 7.

6.

Stem cell transplantation as a dynamical system: are clinical outcomes deterministic?

Toor AA, Kobulnicky JD, Salman S, Roberts CH, Jameson-Lee M, Meier J, Scalora A, Sheth N, Koparde V, Serrano M, Buck GA, Clark WB, McCarty JM, Chung HM, Manjili MH, Sabo RT, Neale MC.

Front Immunol. 2014 Dec 3;5:613. doi: 10.3389/fimmu.2014.00613. eCollection 2014. Review.

7.

In silico Derivation of HLA-Specific Alloreactivity Potential from Whole Exome Sequencing of Stem-Cell Transplant Donors and Recipients: Understanding the Quantitative Immunobiology of Allogeneic Transplantation.

Jameson-Lee M, Koparde V, Griffith P, Scalora AF, Sampson JK, Khalid H, Sheth NU, Batalo M, Serrano MG, Roberts CH, Hess ML, Buck GA, Neale MC, Manjili MH, Toor AA.

Front Immunol. 2014 Nov 6;5:529. doi: 10.3389/fimmu.2014.00529. eCollection 2014. Review.

8.

Are alternative donors really still "alternative?".

Kanakry CG, Luznik L.

Biol Blood Marrow Transplant. 2014 Oct;20(10):1463-4. doi: 10.1016/j.bbmt.2014.07.029. Epub 2014 Jul 31. No abstract available.

9.

Identification of a permissible HLA mismatch in hematopoietic stem cell transplantation.

Fernandez-Viña MA, Wang T, Lee SJ, Haagenson M, Aljurf M, Askar M, Battiwalla M, Baxter-Lowe LA, Gajewski J, Jakubowski AA, Marino S, Oudshoorn M, Marsh SG, Petersdorf EW, Schultz K, Turner EV, Waller EK, Woolfrey A, Umejiego J, Spellman SR, Setterholm M.

Blood. 2014 Feb 20;123(8):1270-8. doi: 10.1182/blood-2013-10-532671. Epub 2014 Jan 9.

10.

Which donor or graft source should you choose for the strongest GVL? Is there really any difference.

Weisdorf D.

Best Pract Res Clin Haematol. 2013 Sep;26(3):293-6. doi: 10.1016/j.beha.2013.10.010. Epub 2013 Oct 15. Review.

11.

The major histocompatibility complex: a model for understanding graft-versus-host disease.

Petersdorf EW.

Blood. 2013 Sep 12;122(11):1863-72. doi: 10.1182/blood-2013-05-355982. Epub 2013 Jul 22. Review.

12.

Multiple mismatches at the low expression HLA loci DP, DQ, and DRB3/4/5 associate with adverse outcomes in hematopoietic stem cell transplantation.

Fernández-Viña MA, Klein JP, Haagenson M, Spellman SR, Anasetti C, Noreen H, Baxter-Lowe LA, Cano P, Flomenberg N, Confer DL, Horowitz MM, Oudshoorn M, Petersdorf EW, Setterholm M, Champlin R, Lee SJ, de Lima M.

Blood. 2013 May 30;121(22):4603-10. doi: 10.1182/blood-2013-02-481945. Epub 2013 Apr 17.

13.

Advances in predicting acute GVHD.

Harris AC, Ferrara JL, Levine JE.

Br J Haematol. 2013 Feb;160(3):288-302. doi: 10.1111/bjh.12142. Epub 2012 Dec 4. Review.

14.

Graft-versus-host disease induced graft-versus-leukemia effect: greater impact on relapse and disease-free survival after reduced intensity conditioning.

Weisdorf D, Zhang MJ, Arora M, Horowitz MM, Rizzo JD, Eapen M.

Biol Blood Marrow Transplant. 2012 Nov;18(11):1727-33. doi: 10.1016/j.bbmt.2012.06.014. Epub 2012 Jul 2.

15.

Practice variation in physician referral for allogeneic hematopoietic cell transplantation.

Pidala J, Craig BM, Lee SJ, Majhail N, Quinn G, Anasetti C.

Bone Marrow Transplant. 2013 Jan;48(1):63-7. doi: 10.1038/bmt.2012.95. Epub 2012 Jun 18.

16.

What Next? The Next Transit from Biology to Diagnostics: Next Generation Sequencing for Immunogenetics.

Gabriel C, Stabentheiner S, Danzer M, Pröll J.

Transfus Med Hemother. 2011 Oct;38(5):308-317. Epub 2011 Sep 25.

17.

Anti-thymocyte globulin for conditioning in matched unrelated donor hematopoietic cell transplantation provides comparable outcomes to matched related donor recipients.

Portier DA, Sabo RT, Roberts CH, Fletcher DS, Meier J, Clark WB, Neale MC, Manjili MH, McCarty JM, Chung HM, Toor AA.

Bone Marrow Transplant. 2012 Dec;47(12):1513-9. doi: 10.1038/bmt.2012.81. Epub 2012 May 14.

18.

TNF-inhibition with etanercept for graft-versus-host disease prevention in high-risk HCT: lower TNFR1 levels correlate with better outcomes.

Choi SW, Stiff P, Cooke K, Ferrara JL, Braun T, Kitko C, Reddy P, Yanik G, Mineishi S, Paczesny S, Hanauer D, Pawarode A, Peres E, Rodriguez T, Smith S, Levine JE.

Biol Blood Marrow Transplant. 2012 Oct;18(10):1525-32. doi: 10.1016/j.bbmt.2012.03.013. Epub 2012 Mar 30.

19.

Outcomes after matched unrelated donor versus identical sibling hematopoietic cell transplantation in adults with acute myelogenous leukemia.

Saber W, Opie S, Rizzo JD, Zhang MJ, Horowitz MM, Schriber J.

Blood. 2012 Apr 26;119(17):3908-16. doi: 10.1182/blood-2011-09-381699. Epub 2012 Feb 10.

20.

Chronic myelogenous leukemia: role of stem cell transplant in the imatinib era.

Jain N, van Besien K.

Hematol Oncol Clin North Am. 2011 Oct;25(5):1025-48, vi. doi: 10.1016/j.hoc.2011.09.003. Review.

Supplemental Content

Support Center